Provided by Tiger Trade Technology Pte. Ltd.

TEMA ONCOLOGY ETF

41.53
-0.2349-0.56%
Post-market: 41.47-0.0585-0.14%19:30 EDT
Volume:28.72K
Turnover:1.20M
Market Cap:203.90M
PE:- -
High:42.30
Open:42.30
Low:41.47
Close:41.76
52wk High:47.00
52wk Low:26.62
Shares:4.91M
Float Shares:4.91M
Volume Ratio:1.14
T/O Rate:0.58%
Dividend:0.02
Dividend Rate:0.05%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Atai Beckley Holds Shareholder Meeting, Quorum Met with 65.6% Shares Represented

Reuters
·
Sep 09

Structure weakness ‘disconnected’ from underlying data, says Jefferies

TIPRANKS
·
Sep 09

Eli Lilly Stock (LLY) Falls on Competitor Novartis’ Cholesterol Drug Setback

TIPRANKS
·
Sep 09

Medicus Pharma Sharpened Strategy Centers on Precision Oncology and Targeted Rare Disease Programs

TIPRANKS
·
Sep 08

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

TIPRANKS
·
Sep 08

5万治疗费背后,“毛孩子”的晚年谁来守护?宠物抗癌险应运而生

Deep News
·
Sep 08

AlzeCure Pharma to Present at Aktiedagen Event in Stockholm

Reuters
·
Sep 08

ASB Ventures-Backed Boundary Zhikong’s Navista eVTOL Navigation System Enters CAAC Airworthiness Review

Reuters
·
Sep 07

Novartis Cholesterol Setback Tests Hopes for Emerging Heart Disease Drugs

Reuters
·
Sep 07

Healthcare Stocks Pick up Steam as Investors Play Offense and Defense

Dow Jones
·
Sep 05

Lilly Targets Type 1 Diabetes With New Tirzepatide Study: What Investors Should Watch

TIPRANKS
·
Sep 05

Eli Lilly Stock (LLY) Gets a Bullish Note from JPMorgan Chase

TIPRANKS
·
Sep 04

Healthcare Stocks Pick up Steam as Investors Play Offense and Defense

Dow Jones
·
Sep 04

Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Teva Pharmaceutical (TEVA)

TIPRANKS
·
Sep 03

Aspen Sees Mounjaro Africa Sales Above $124 Million in 2027

Reuters
·
Sep 03

Superluminal Medicines: Financing Led by Bvf Partners; Alongside Existing Investors Nvidia, Eli Lilly & Co, Cooley, and Gaingels, Among Others

THOMSON REUTERS
·
Sep 03

Rothschild & Co Redburn Adjusts PT on Eli Lilly and Co. to $930 From $915, Keeps Neutral Rating

MT Newswires Live
·
Sep 03

Buy Rating Reiterated on Daraxonrasib Strength, RASolve 301 Upsizing, and Unchanged $315 Price Target

TIPRANKS
·
Sep 03

NEJM publishes Phase 1/2 clinical data on daraxonrasib

TIPRANKS
·
Sep 03

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

GlobeNewswire
·
Sep 03